Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Heat Shock who wrote (208)	2/5/2003 4:32:25 PM
From: Heat Shock	of 236

To all, text from Post #6004499 over on stockhouse.ca: SUBJECT: RE: Canaccord out with STRONG BUY RATING TODAY Stressgen Biotechnologies (SSB : TSX : C$1.63) - Strong Buy - 12-month target price: C$4.00 Shameze Rampertab Comment: Stressgen Q4/2002 beats expectations Stressgen's Q4/2002 EPS of $(0.06) beat our expectation of $(0.13), and improved on the previous year's Q4 loss of $(0.22). Roche has been paying for 58% and 56% of total R&D expenses in Q3 and Q4, respectively. This has resulted in a reduced cash burn of 60% in the second half of the year. Cash of $46 million at the end of the year, representing over two years at expected burn, excluding milestone payments from Roche. Stressgen was granted a European patent covering compositions of the fusion of a heat shock protein with various human papillomavirus antigens. These results validate the positive structure of the Roche partnership in conserving cash. We have revised our financial model due to the strong collaborative R&D revenue from Roche, partially offset by the weaker bioreagent sale growth. We are decreasing our loss per share from $(0.21) to $(0.07) in 2003, which includes $15.0 million of milestone payments. Excluding the milestone, we are expecting a loss of $(0.32)/share. We continue to value Stressgen on a discounted price-to-earnings valuation incorporating 2007 forecasted earnings of $0.55, using a 30% discount and 20 times multiple. We maintain a STRONG BUY recommendation and 12-month target price of $4.00. Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next